Efficacy and safety study of 4 doses of QGE031 in patients 18-50 years of age with peanut allergy

Mise à jour : Il y a 5 ans
Référence : EUCTR2011-000631-92

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The increase in the threshold dose of peanut protein that induces objective hypersensitivity reactions after treatment assessed by double-blind, placebo-controlled oral food challenges (DBPCFC) before and after 16 weeks of treatment.


Critère d'inclusion

  • Peanut Allergy